Press Room

News / Mar 10, 2021

It's B Corp Month

We are proud to be a B Corporation.

B Corp Month | Hovione

This March is B Corp month – a whole month dedicated to celebrating businesses who are doing things differently and driving change and raising awareness in a globally coordinated social media effort to celebrate B Corps.

In 2017, we became a Certified B Corp. Being the first Chemical/ Pharmaceutical Company integrating an innovative community of companies that use the power of business to solve social and environmental problems.

Being a B Corporation means that to ensure our long‑term viability we will contribute positively to economic, environmental, and social sustainability.

B Corp Month | Hovione

As a Certified B CorporationTM we want to contribute to redefine success in business, meeting the highest standards of social and environmental performance, setting our Team Members for success and personal satisfaction, and aspiring to use the power of markets to solve social and environmental problems. Collectively, B Corps lead a growing global movement of people using business as a force for goodTM.

We are proud to be a B Corporation.

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

 

Learn more about Hovione being a B Corporation

 

 

B Corporation Certification logo | Hovione

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025